Clinical Trial Update: Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating WX-0593 in ALK-positive non-small cell lung cancer (NSCLC) patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• WX-0593

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN